gnckКолопроктологияKoloproktologia2073-75562686-7303Russian Association of Coloproctology10.33878/2073-7556-2025-24-2-84-85gnck-2053Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESКомментарии редколлегии к статье «Непосредственные результаты предоперационной химиотаргетной терапии у больных раком прямой кишки», авторы: Добродеев А.Ю. Тарасова А.С., Афанасьев С.Г., Костромицкий Д.Н., Пономарева А.А., Бабышкина Н.Н., Дронова Т.А., Ларионова И.В., Юнусова Н.В.Editorial’s comment to the article “Immediate Results of Preoperative Chemo-targeting Therapy in Patients with Rectal Cancer” by the authors: Aleksey Yu. Dobrodeev, Anna S. Tarasova, Sergey G. Afanasyev, Dmitry N. Kostromitsky, Anastasia A. Ponomareva, Natalia N. Babyshkina, Tatyana A. Dronova, Irina V. Larionova, Natalia V. YunusovaРедакционнаястатьяEditorialArticle2025170520252428485Copyright © Редакционная с., 20252025Редакционная с.Editorial A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.ruproctology.com/jour/article/view/2053
.
ReferencesФедянин М.Ю., Гладков О.А., Гордеев С.С., и соавт. Рак ободочной кишки, ректосигмоидного соединения и прямой кишки. Практические рекомендации RUSSCO, часть 1.1. Злокачественные опухоли. 2024;14(3s2):263–322.Fedyanin M.Yu., Gladkov O.A., Gordeev S.S., et al. Cancer of the colon, rectosigmoid junction and rectum. RUSSCO prectical recommendation, part 1.1. Malignant tumors. 2024;14(3s2):263–322. (In Russ.).Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetux-imab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol. 2012;30(14):1620–1627.Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetux-imab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol. 2012;30(14):1620–1627.Liu C, Zhong C, Liu H, et al. Modified FOLFOX6 with Cetuximab versus with Radiotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: A Single-Center, Prospective, Randomized Controlled Trial. Biol Pharm Bull. 2024;47(10):1675–1681.Liu C, Zhong C, Liu H, et al. Modified FOLFOX6 with Cetuximab versus with Radiotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: A Single-Center, Prospective, Randomized Controlled Trial. Biol Pharm Bull. 2024;47(10):1675–1681.Velenik V, Ocvirk J, Oblak I, et al. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol. J Eur Soc Surg Oncol. 2010;36(3):244–250.Velenik V, Ocvirk J, Oblak I, et al. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol. J Eur Soc Surg Oncol. 2010;36(3):244–250.
The authors declare that there are no conflicts of interest present.